191 related articles for article (PubMed ID: 34869703)
21. Short-Term Cooling Increases Plasma ANGPTL3 and ANGPTL8 in Young Healthy Lean Men but Not in Middle-Aged Men with Overweight and Prediabetes.
Janssen LGM; Jauhiainen M; Olkkonen VM; Haridas PAN; Nahon KJ; Rensen PCN; Boon MR
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31416197
[TBL] [Abstract][Full Text] [Related]
22. ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.
Xiao HB; Wang JY; Sun ZL
Exp Mol Pathol; 2017 Dec; 103(3):242-248. PubMed ID: 29104012
[TBL] [Abstract][Full Text] [Related]
23. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
24. The Angiopoietin-Like Protein 3 and 8 Complex Interacts with Lipoprotein Lipase and Induces LPL Cleavage.
Jin N; Matter WF; Michael LF; Qian Y; Gheyi T; Cano L; Perez C; Lafuente C; Broughton HB; Espada A
ACS Chem Biol; 2021 Mar; 16(3):457-462. PubMed ID: 33656326
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
26. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
27. Angiopoietin-like 3 in lipoprotein metabolism.
Kersten S
Nat Rev Endocrinol; 2017 Dec; 13(12):731-739. PubMed ID: 28984319
[TBL] [Abstract][Full Text] [Related]
28. Decoding the role of angiopoietin-like protein 4/8 complex-mediated plasmin generation in the regulation of LPL activity.
Chen YQ; Zhen EY; Russell AM; Ehsani M; Siegel RW; Qian Y; Konrad RJ
J Lipid Res; 2023 Oct; 64(10):100441. PubMed ID: 37666362
[TBL] [Abstract][Full Text] [Related]
29. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition.
Chen YQ; Pottanat TG; Zhen EY; Siegel RW; Ehsani M; Qian YW; Konrad RJ
J Lipid Res; 2021; 62():100068. PubMed ID: 33762177
[TBL] [Abstract][Full Text] [Related]
30. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.
Shimamura M; Matsuda M; Yasumo H; Okazaki M; Fujimoto K; Kono K; Shimizugawa T; Ando Y; Koishi R; Kohama T; Sakai N; Kotani K; Komuro R; Ishida T; Hirata K; Yamashita S; Furukawa H; Shimomura I
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):366-72. PubMed ID: 17110602
[TBL] [Abstract][Full Text] [Related]
31. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism.
Kersten S
J Lipid Res; 2021; 62():100150. PubMed ID: 34801488
[TBL] [Abstract][Full Text] [Related]
32. A unified model for regulating lipoprotein lipase activity.
Zhang R; Zhang K
Trends Endocrinol Metab; 2024 Jun; 35(6):490-504. PubMed ID: 38521668
[TBL] [Abstract][Full Text] [Related]
33. Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes.
Christopoulou E; Elisaf M; Filippatos T
Dis Markers; 2019; 2019():6578327. PubMed ID: 30944669
[TBL] [Abstract][Full Text] [Related]
34. Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity.
Chen YQ; Yang Y; Zhen EY; Beyer TP; Li H; Wen Y; Ehsani M; Jackson N; Xie K; Jung H; Scheithauer JL; Kumari A; Birrane G; Russell AM; Balasubramaniam D; Liao Z; Siegel RW; Qian Y; Ploug M; Young SG; Konrad RJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2322332121. PubMed ID: 38625948
[TBL] [Abstract][Full Text] [Related]
35. Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia.
Tarugi P; Bertolini S; Calandra S
J Biomed Res; 2019 Apr; 33(2):73-81. PubMed ID: 29752428
[TBL] [Abstract][Full Text] [Related]
36. Evinacumab to treat hypercholesterolemia.
Engler C; Ebenbichler C
Drugs Today (Barc); 2021 Oct; 57(10):607-619. PubMed ID: 34713869
[TBL] [Abstract][Full Text] [Related]
37. The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation.
Abu-Farha M; Ghosh A; Al-Khairi I; Madiraju SRM; Abubaker J; Prentki M
Prog Lipid Res; 2020 Nov; 80():101067. PubMed ID: 33011191
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.
Wang Y; Gusarova V; Banfi S; Gromada J; Cohen JC; Hobbs HH
J Lipid Res; 2015 Jul; 56(7):1296-307. PubMed ID: 25954050
[TBL] [Abstract][Full Text] [Related]
39. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
[TBL] [Abstract][Full Text] [Related]
40. Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities.
Gunn KH; Gutgsell AR; Xu Y; Johnson CV; Liu J; Neher SB
J Biol Chem; 2021; 296():100312. PubMed ID: 33482195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
